Airna, a Cambridge, MA-based biotech company advancing RNA editing therapeutics to restore the health of patients with rare and common diseases, closed a $60m financing round.
The financing, which brought the total Series A funding to $90m, was led by Forbion with participation from Ono Venture Investment, Alexandria Venture Investments, and other new investors, as well as AIRNA’s existing syndicate, including ARCH Venture Partners and ND Capital.
The company intends to use the funds to advance its lead product candidate into clinical trials and further develop its broad pipeline.
Led by Kris Elverum, President and Chief Executive Officer, Airna is pioneering the discovery and development of RNA editing therapeutics to transform the lives of patients with rare and common diseases. Its RESTORE+™ platform is based on research by academic co-founders Thorsten Stafforst (University of Tübingen) and Jin Billy Li (Stanford University), who were the first to elucidate a therapeutic approach for precise editing of RNA.
Airna is advancing its first therapeutic program, a best-in-class product candidate to treat the inherited genetic disease alpha-1 antitrypsin deficiency (AATD), as well as a pipeline of therapeutic candidates to address multiple diseases with high unmet need.
The company has research operations in Tübingen, Germany.
FinSMEs
31/07/2024